🟢 Tiziana Life Sciences is trading 12.83% up in pre-market after foralumab multiple sclerosis collaboration MOU

Tiziana Life Sciences is trading 12.83% up in pre-market at $0.87 after announcing a September 17, 2026 memorandum of understanding.

• The MOU is with King Abdullah International Medical Research Center and the Foundation for Neurologic Diseases.
• The proposed collaboration will evaluate intranasal foralumab alongside anti-CD20 therapy in relapsing-remitting multiple sclerosis patients responding poorly to existing treatment.
• The MOU is the clearest company-specific catalyst for the pre-market advance.